Bespak has signed an MOU with SNBL to provide immediate and exclusive global access to SNBL’s proprietary nasal dry powder ...
Galderma has announced new NEMLUVIO data to be presented at Fall Clinical 2026, including a post‑hoc analysis from the ...
AbbVie has announced that the SMC has accepted AQUIPTA (atogepant) for acute migraine treatment in adults, only if at least two triptans were previously tried without sufficient effect, or triptans ...
Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...
Alnylam UK Limited has welcomed a Scottish Medicines Consortium decision to accept vutrisiran for adults with ATTR‑CM, enabling eligible patients to access AMVUTTRA through NHS ...
Northwest Biotherapeutics and NHS Blood and Transplant have agreed a collaboration to support production of DCVax-L, a ...
Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic ...
Atrogi has announced positive human data for ATR‑258, its first‑in‑class oral GRK2‑biased β2‑adrenergic modulator designed to improve muscle function and body composition. In an 8‑week ...
Mums whose babies developed life‑threatening sepsis and meningitis from group B streptococcus are urging pregnant women to ...
NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...
Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes. The SYNCHRONIZE‑2 ...
Quotient Sciences and Acesion Pharma have formed a new collaboration to apply AI‑enhanced formulation development within Quotient’s Translational Pharmaceutics platform. The partnership will support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results